Comparing the current results to its competitors, Elicio Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.55 %, recorded in the same quarter.
Elicio Therapeutics Inc , slower than the average decrease reported by the company's competitors of -83.9 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -83.9 %
December 12, 2024
Elicio Therapeutics Promising Outlook Amidst Competitive Financial Landscape: A Look at the ELI-002 Phase 1 AMPLIFY-201 Study Results Elicio Therapeutics, a company at the forefront of innovation in cancer treatment, recently showcased its advancements at the ESMO Immuno-Oncology Congress 2024. The company presented updated results from its ELI-002 Phase 1 AMPLIFY-201 study, highlighting encouraging developments in the treatment of patients with certain forms of cancer. These results underscore Elicio Therapeutics commitment to transforming cancer care by harnessing cutting-edge immunotherapy approaches.The updated Phase 1 data reflect a notable achievement: a median recurrence-free survival (mRFS) of 16.3...
April 5, 2024
Elicio Therapeutics to Present Promising Clinical and Preclinical Data on Immunotherapies at AACR Annual MeetingBOSTON, April 05, 2024 - Elicio Therapeutics, a pioneering biotechnology company focused on developing innovative immunotherapies for cancer treatment, has announced its participation in the prestigious American Association for Cancer Research (AACR) Annual Meeting in San Diego, California from April 5-10, 2024. The company will unveil updates on its pipeline of investigational candidates, including ELI-002, ELI-007, and ELI-008, showcasing potentially groundbreaking advancements in cancer immunotherapy.The highlight of Elicio s presentation will be the updated immunogenicity data from the ongoing ...
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Sources:
Elicio Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Elicio Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
